Mark Bachleda
Plus aucun poste en cours
Fortune : 2 277 $ au 30/04/2024
Historique de carrière de Mark Bachleda
Anciens postes connus de Mark Bachleda
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 12/10/2021 | 09/08/2023 |
| JUNO THERAPEUTICS INC | Sales & Marketing | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Formation de Mark Bachleda
| University of Illinois | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Bourse
- Insiders
- Mark Bachleda
- Expérience
